当前位置:首页 > 研究报告 > 医疗健康 > 医药产业 > Investment and Forecast Report on China Chemical Medicine Industry, 2015-2019

Investment and Forecast Report on China Chemical Medicine Industry, 2015-2019

中国投资咨询网www.ocn.com.cn2015/12/23
  • 首次出版:   最新修订:August 2012
  • 报告主编:
  • 交付方式:特快专递(2-3天送达)
  • 中文版全价:RMB9600 印刷版:RMB8600 电子版:RMB9100
  • 英文版全价:USD6800 印刷版:USD5800 电子版:USD5800
  • 定购电话:0755-82571522、82571566、400-008-1522
  • 24小时服务热线:138 0270 8576
大健康产业咨询解决方案,点击进入>>

ChapterⅠPharmaceutical industry
  1.1 Overview of international pharmaceutical industry
    1.1.1 Overview of the development of the global pharmaceutical industry
    1.1.2 Large-scale mergers and acquisitions in the global pharmaceutical industry have started
    1.1.3 Analysis of the global pharmaceutical industry in 2010
    1.1.4 Analysis of the global pharmaceutical market ’ development in 2011
    1.1.5 Forecast of development of the global pharmaceutical market
  1.2 Overview of the domestic pharmaceutical industry in general
    1.2.1 The development course of China's pharmaceutical industry in the past three decades since the reform and opening up
    1.2.2 Chinese pharmaceutical industry is in the critical period of adjustment and upgrade
    1.2.3 Multinational pharmaceutical companies in China's pharmaceutical market
    1.2.4 The main trend of mergers and acquisitions of the domestic pharmaceutical market
  1.3 Data analysis of the pharmaceutical industry in 2008-2012
    1.3.1 Analysis of operation data of the pharmaceutical industry in 2008
    1.3.2 The development of Chinese pharmaceutical industry in 2009
    1.3.3 The operations of China's pharmaceutical industry in 2010
    1.3.4 Operation analysis of China's pharmaceutical industry in 2011
    1.3.5 The operations of China's pharmaceutical industry in 2012
  1.4 Analysis of the rural medical market
    1.4.1 Basic rural medical market
    1.4.2 The situation of township and rural medical market
    1.4.3 Characteristics of rural medical market
    1.4.4 Channel problems hinder the development of the rural medical market
  1.5 Analysis of the mode of mergers and acquisitions in pharmaceutical market
    1.5.1 The difference between domestic and international M & A activities
    1.5.2 Risk of M & A
    1.5.3 Mode of M & A
  1.6 Problems in the pharmaceutical industry and its countermeasures
    1.6.1 Problems in Chinese pharmaceutical industry
    1.6.2 Government should strengthen policy guidance
    1.6.3 The increasing concentration of the pharmaceutical industry
    1.6.4 Chinese pharmaceutical industry is exploring the international road
ChapterⅡ Chemical medicine industry
  2.1 Development of China’s chemical pharmaceutical industry in 2008-2010
    2.1.1 Development of China’s chemical pharmaceutical industry in 2008
    2.1.2 Development of China’s chemical pharmaceutical industry in 2009
    2.1.3 Development of China’s chemical pharmaceutical industry in 2010
  2.2 The development of China’s chemical pharmaceutical industry in 2011
    2.2.1 The share of GDP The industrial output value of chemical medicine change
    2.2.2 The proportions of chemical medicine sector investment to total investment
    2.2.3 Supply analysis of China’s chemical pharmaceutical industry
    2.2.4 Demand analysis of China’s chemical pharmaceutical industry
  2.3 Analysis of domestic chemical and pharmaceutical companies
    2.3.1 Analysis of the competitive environment for the pharmaceutical companies
    2.3.2 Characteristics of domestic chemical and pharmaceutical companies
    2.3.3 Impact of inward international business on China’s chemical pharmaceutical enterprises
    2.3.4 Resources integration drive the development of pharmaceutical companies in the post-GMP era
    2.3.5 Profit model for China’s chemical pharmaceutical companies
Chapter Ⅲ Financial analysis of China’s pharmaceutical preparations manufacturing industry
  3.1 Economic scale of China’s chemical preparations manufacturing industry
    3.1.1 Sales scale of China’s chemical preparations manufacturing industry during 2008-Jun 2012
    3.1.2 Profit scale of China’s chemical preparations manufacturing industry during  2008-Jun 2012
    3.1.3 Asset scale of China’s chemical preparations manufacturing industry during  2008-Jun 2012
  3.2 Profitability analysis of China’s pharmaceutical preparations manufacturing industry
    3.2.1 Loss-generating enterprises preparations of chemical preparations manufacturing industry during  2008-Jun 2012
    3.2.2 Gross margin of chemical preparations manufacturing industry during  2008-Jun 2012
    3.2.3 Cost and expense ratios of chemical preparations manufacturing industry during  2008-Jun 2012
    3.2.4 Rate of return on sale of chemical preparations manufacturing industry during  2008-Jun 2012
  3.3 Analysis of enterprises' operating capacity for China’s chemical preparations manufacturing industry
    3.3.1 Accounts receivable turnover of China’s chemical preparations manufacturing industry during  2008-Jun 2012
    3.3.2 Current assets turnover of China’s chemical preparations manufacturing industry during  2008-Jun 2012
    3.3.3 Total assets turnover of China’s chemical preparations manufacturing industry during  2008-Jun 2012
  3.4 Debt-paying ability analysis of China’s chemical preparations manufacturing industry
    3.4.1 Asset-liability ratio of China’s chemical preparations manufacturing industry during  2008-Jun 2012
    3.4.2 Interest cover ratio of China’s chemical preparations manufacturing industry during  2008-Jun 2012
  3.5 Comprehensive evaluation of financial situation of Chinese chemical preparations manufacturing
    3.5.1 Comprehensive evaluation of financial situation of chemical preparations manufacturing
    3.5.2 Economic factors which impact the financial condition of chemical preparations manufacturing
Chapter Ⅳ Financial analysis of China’s chemical raw medicine manufacturing industry
  4.1 Economic scale of China’s chemical raw medicine manufacturing industry
    4.1.1 Sales scale of China’s chemical raw medicine manufacturing industry during 2008-Jun 2012
    4.1.2 Profit scale of China’s chemical raw medicine manufacturing industry during  2008-Jun 2012
    4.1.3 Asset scale of China’s chemical raw medicine manufacturing industry during  2008-Jun 2012
  4.2 Profitability analysis of China’s chemical raw medicine manufacturing industry
    4.2.1 Loss-generating enterprises preparations of chemical raw medicine manufacturing industry during  2008-Jun 2012
    4.2.2 Gross margin of chemical raw medicine manufacturing industry during  2008-Jun 2012
    4.2.3 Cost and expense ratios of chemical raw medicine manufacturing industry during  2008-Jun 2012
    4.2.4 Rate of return on sale of chemical raw medicine manufacturing industry during  2008-Jun 2012
  4.3 Analysis of enterprises' operating capacity for China’s chemical raw medicine manufacturing industry
    4.3.1 Accounts receivable turnover of China’s chemical raw medicine manufacturing industry during  2008-Jun 2012
    4.3.2 Current assets turnover of China’s chemical raw medicine manufacturing industry during  2008-Jun 2012
    4.3.3 Total assets turnover of China’s chemical raw medicine manufacturing industry during  2008-Jun 2012
  4.4 Debt-paying ability analysis of China’s chemical raw medicine manufacturing industry
    4.4.1 Asset-liability ratio of China’s chemical raw medicine manufacturing industry during  2008-Jun 2012
    4.4.2 Interest cover ratio of China’s chemical raw medicine manufacturing industry during  2008-Jun 2012
  4.5 Comprehensive evaluation of financial situation of Chinese chemical raw medicine manufacturing
    4.5.1 Comprehensive evaluation of financial situation of chemical raw medicine manufacturing
    4.5.2 Economic factors which impact the financial condition of chemical raw medicine manufacturing industry
Chapter V Analysis of the domestic chemical raw materials industry
  5.1 Status of chemical raw materials industry
    5.1.1 Low-priced exports of chemical raw materials lead to trade disputes
    5.1.2 Raw materials export is very hard for China
    5.1.3 Chemical raw materials industry mingled hope and fear
    5.1.4 Worries about China's chemical raw materials
  5.2 Chemical raw materials production in the major provinces of China during 2010- Jul 2012
    5.2.1 Chemical raw materials production in the major provinces of China in 2010
    5.2.2 Chemical raw materials production in the major provinces of China in 2011
    5.2.3 Chemical raw materials production in the major provinces of China during January to July 2012
  5.3 Import and export of chemical raw materials
    5.3.1China’s import and export of chemical raw materials in 2008
    5.3.2 Analysis of the exports of chemical raw materials in 2009
    5.3.3 Imports and exports of chemical raw materials in China in 2010
    5.3.4 Analysis of imports and exports of chemical raw materials in 2011
    5.3.5 Imports and exports of chemical raw materials in 2012
Chapter VI Analysis of antibiotics
  6.1 Overview of antibiotic-associated
    6.1.1 Definition and Classification
    6.1.2 Principles of antibiotics
    6.1.3 Use of antibiotics
  6.2 Antibiotics market analysis
    6.2.1 Development of the main varieties of domestic antibiotic
    6.2.2 Overview of U.S. antibiotics global trade situation
    6.2.3 Analysis of China’s antibiotics export
    6.2.4 Antibiotics is the largest amount of China's hospital clinical use
    6.2.5 Antibiotics Industrial Technology Innovation Alliance has set up
    6.2.6 China is facing a new business environment for development of antibiotics
  6.3 Analysis of cephalosporin antibiotics
    6.3.1 Definition and classification
    6.3.2 Import and export of cephalosporins
    6.3.3 Cephalosporin market rebound After the Chinese New Year of 2011
    6.3.4 Worries about China’s cephalosporins indusry in the rapid development
    6.3.5 Cephalosporin antibiotics have a stable market
    6.3.6 Cefprozil has much brighter future
  6.4 Tetracyclines antibiotics
    6.4.1 Overview of tetracyclic antibiotics
    6.4.2 Overview of world market tetracycline
    6.4.3 Analysis of China’s exports of tetracycline
    6.4.4 Prospect of China tetracycline
  6.5 Macrolides
    6.5.1 Overview of macrolide antibiotic-associated
    6.5.2 Progress in research and development of macrolide antibiotics
    6.5.3 Analysis of macrolide export
    6.5.4 Macrolide antibiotics had stong momentum
    6.5.5 Analysis of the second-generation macrolide antibiotics
  6.6 Quinolones
    6.6.1 The development of quinolones
    6.6.2 Pharmacology and medicinal
    6.6.3 China developed gatifloxacin class of drugs of China own proprietary first time
Chapter VII The vitamins API
  7.1 Overview of the international market
    7.1.1 Opportunities and challenges coexist in world vitamin industry
    7.1.2 The composition of the international vitamin market
    7.1.3 A new pattern of competition of global vitamin industry
    7.1.4 International vitamin market trends
  7.2 Overview of domestic vitamin market
    7.2.1 Overview of Chinese vitamin industry
    7.2.2 The domestic vitamin market in 2009
    7.2.3 Analysis of China's exports of vitamins in 2010
    7.2.4 Overview of China vitamin market in 2011
    7.2.5 The future development potential of vitamin industry
  7.3 Analysis of fat-soluble vitamins
    7.3.1 Introduction of fat-soluble vitamins
    7.3.2 Market analysis of vitamin AD
    7.3.3 Vitamin D2 has a bright market future
    7.3.4 Vitamin D production exceeded multinational monopoly
  7.4 Analysis of water-soluble vitamins
    7.4.1 Introduction of water-soluble vitamins
    7.4.2 Analysis of China's exports of vitamin C in 2011
    7.4.3 Market situation of vitamin B2 in domestic market
    7.4.4 Vitamin B12 and its derivatives have broad market prospects
    7.4.5 China has achieved self-sufficiency in the production of Vitamin H
Chapter VIII Analysis on the drugs of major category
  8.1 Diabetes drugs
    8.1.1 Development of the global diabetes drug market
    8.1.2 New technologies will break the pattern of the global diabetes drug market
    8.1.3 Domestic and foreign pharmaceutical companies compete for the Chinese diabetes drug market
    8.1.4 Sale pattern of diabetes drug market
    8.1.5 Forecast of China diabetes drug market 2012
  8.2 Cardiovascular drugs
    8.2.1 Summary of U.S. cardiovascular drugs market development
    8.2.2 Summary of cardiovascular drugs market in China
    8.2.3 Competition pattern of China cardiovascular drug market
    8.2.4 China antihypertensive drugs market grow fast
    8.2.5 Foreign brands dominated the domestic market of antihypertensive drugs
  8.3 Cold medicine
    8.3.1 Consumer behavior analysis on Chinese cold medicine market
    8.3.2 Chinese cold medicine retail market structure analysis
    8.3.3 Impact of "restricted order" on the domestic cold drug market
    8.3.4 Cold medicine marketing strategies
    8.3.5 Cold medicine suffered a crisis of confidence and measures in 2011
  8.4 Other drugs
    8.4.1 Market structure of China non-steroidal anti-inflammatory drugs
    8.4.2 Non-steroidal anti-inflammatory drug market grow rapidly
    8.4.3 Overview of antiviral drug market
    8.4.4 Bright prospect of anti-allergic rhinitis drug market
Chapter IX Analysis of listed companies
  9.1 Harbin Pharmaceutical Group Co., Ltd.(HPGC)
    9.1.1 Introduction
    9.1.2 Operating analysis of HPGC in 2010
    9.1.3 Operating analysis of HPGC in 2011
    9.1.4 Operating analysis of HPGC in the first half of 2012
    9.1.5 HPGC actively widen the innovative platform
  9.2 North China Pharmaceutical Co., Ltd.(NCPC)
    9.2.1 Introduction
    9.2.2 Operating analysis of NCPC in 2010
    9.2.3 Operating analysis of NCPC in 2011
    9.2.4 Operating analysis of NCPC in the first half of 2012
    9.2.5 NCPC carry out the strategic transformation to promote preparation export
  9.3 Shandong Lukang Pharmaceutical Co.,Ltd. (LKPC)
    9.3.1 Introduction
    9.3.2 Operating analysis of LKPC in 2010
    9.3.3 Operating analysis of LKPC in 2011
    9.3.4 Operating analysis of LKPC in the first half of 2012
    9.3.5 Science and technology lead the new development of LKPC
  9.4 Guangzhou Baiyunshan Pharmaceutical Co.,Ltd..(BYS)
    9.4.1 Introduction
    9.4.2 Operating analysis of BYS in 2010
    9.4.3 Operating analysis of BYS in 2011
    9.4.4 Operating analysis of BYS in the first half of 2012
    9.4.5 BYS returns the professional management
  9.5 Zhejiang Hisun Pharmaceutical Co.,Ltd..(HISUN)
    9.5.1 Introduction
    9.5.2 Operating analysis of HISUN in 2010
    9.5.3 Operating analysis of HISUN in 2011
    9.5.4 Operating analysis of HISUN in the first half of 2012
    9.5.5 HISUN promote development by innovation
  9.6 Shandong Xinhua Pharmaceutical Company Limited(XHZY)
    9.6.1 Introduction
    9.6.2 Operating analysis of XHZY in 2010
    9.6.3 Operating analysis of XHZY in 2011
    9.6.4 Operating analysis of XHZY in the first half of 2012
    9.6.5 XHZY regard the Scientific and technological innovation as the core competitiveness
  9.7 Comparative Analysis of Listed Companies
    9.7.1 Profitability analysis
    9.7.2 Growth capacity
    9.7.3 Operating capacity
    9.7.4 Solvency capacity
Chapter X Medical logistics
  10.1 Development of China medical logistics industry
    10.1.1 Current situation of China medicine circulation
    10.1.2 Medical logistics industry is in the period of fully integration
    10.1.3 Characteristics of domestic and foreign medical logistics market
    10.1.4 Analysis on China medical logistics market
    10.1.5 China medical logistics market enters the distributor era
  10.2 Problems analysis on medical logistics
    10.2.1 Problems in China medical logistics
    10.2.2 Duplication of similarprojects and disorderly competition in China medical logistics industry
    10.2.3 Lack of talent in medical logistics
    10.2.4 Serious problem of distribution system in China medical logistics industry
  10.3 Development strategy of medical logistics
    10.3.1 Problems that should be paid attention to in medical logistics industry development
    10.3.2 Supply chain management is the key to develop modern medical logistics
    10.3.3 Domestic medical logistics industry should learn from foreign models
    10.3.4 Competitive strategy that China medical logistics companies compete with foreigners
    10.3.5 China should implement an active medical logistics development policy
  10.4 Case study
    10.4.1 Hong Kong Zuellig Group
    10.4.2 Shenzhen Accord Pharmaceutical Co., Ltd.
    10.4.3 Information creates "Jinxiang Pharmacy " Medical Logistics
  10.5 Prospects of medical logistics industry
    10.5.1 Development prospects of China medical logistics industry
    10.5.2 China medical logistics market trends
    10.5.3 Refrigerated logistics will become the key development area in medical logistics industry
    10.5.4 SWOT analysis on medical logistics development model
Chapter XI Pharmaceutical Marketing
  11.1 Status of pharmaceutical marketing
    11.1.1 Dilemma of China pharmaceutical marketing
    11.1.2 Marketing pattern in GMP post-certification era
    11.1.3 Strange situations in pharmaceutical marketing
  11.2 Analysis of pharmaceutical marketing model
    11.2.1 Total-propaganda marketing model
    11.2.2 Clinic-marketing model
    11.2.3 Conference marketing model
    11.2.4 Advertising hype plus terminal marketing model
    11.2.5 Marketing model innovation about pharmaceutical product
    11.2.6 "SICHUAN SHUZHONG MEDICINE GROUP mode" revitalize generic drugs marketing of the rural market
  11.3 Analysis of pharmaceutical marketing problems
    11.3.1 Two drawbacks of pharmaceutical marketing
    11.3.2 Three mistakes in making pharmaceutical marketing strategy
    11.3.3 Five difficulties on developing rural medical market
    11.3.4 Five marketing difficulties that pharmaceutical companies need to solve
  11.4 Measures of pharmaceutical marketing development
    11.4.1 Marketing strategies after the pharmaceutical reform
    11.4.2 In-depth planning is the direction of pharmaceutical marketing
    11.4.3 Analysis on rural marketing ideas
    11.4.4 Marketing systematic is help with developing the rural market
  11.5 Typical case study
    11.5.1 "white and black" was born to be alive by channel
    11.5.2 Johnson Tylenol find the right way and win opportunities
    11.5.3 The Successful Road of JIANGZHONG Jianweixiaoshi tablets
  11.6 Pharmaceutical marketing trends
    11.6.1 Ten new trends in pharmaceutical marketing
    11.6.2 Ten directions of pharmaceutical distributors development
    11.6.3 Future prospects of pharmaceutical marketing
    11.6.4 Marketing channels of pharmaceutical OTC market in future
Chapter XII Outlook on chemical medicine industry
  12.1 Outlook on China pharmaceutical industry
    12.1.1 Development prospects of pharmaceutical industry
    12.1.2 China pharmaceutical retail market has large space for growth
    12.1.3 Pharmaceutical market development trends
  12.2 Outlook on China chemical medicine industry
    12.2.1 Prospects of China API industry
    12.2.2 Fluorine chemistry will become the basis for new API drug
    12.2.3 Prospects of chemical preparation industry development
    12.2.4 Forecast analysis of China chemical pharmaceutical industry 2012-2016
Chapter XIII Policies and regulations
  13.1 Policy analysis
    13.1.1 The pharmaceutical industry entered into serious policy period through strictly controling drug prices
    13.1.2 Pharmaceutical companies faced two policy challenges
    13.1.3 Strong regulation of false drug advertising
    13.1.4 creating new drugs may obtain fast approval
  13.2 Regulations introduction
    13.2.1 Implementation Plan for the Recent Priorities of the Health Care System Reform
    13.2.2 Drug Administration Law of The People's Republic of China
    13.2.3 Provisions on Supervision and Administration of Pharmaceutical Manufacturing
    13.2.4 Provisions for Drug Registration Administration
    13.2.5 Measures for the Examination of Drug Advertisements
    13.2.6 Provisions on Approval of Generic Drugs
    13.2.7 Drug GMP Certification

  • 图表目录
  •  
***************更多图表目录略***************
本报告目录与内容系中投顾问原创,未经中投顾问书面许可及授权,拒绝任何形式的复制、转载,谢谢!
相关推荐报告
购买流程
温馨提示
    1. 购买报告时请认准"中投顾问"商标,公司从未通过第三方代理,请与本站电话联系购买。
    2. 中投顾问欢迎广大客户上门洽谈与合作,您可以上门浏览报告核实后付款。
相关报告推荐
购买此报告的用户还购买了
联系我们
研究报告热线:
规划咨询热线:
招商咨询热线:
节日值班电话:
深圳总部地址:
0755-82571522
400 008 1522
400 008 0552
400 008 0586
138 0270 8576
广东省深圳市福田区车公庙泰然六路雪松大厦A座4楼
在线咨询: 点击这里给我发消息